Friday, April 20, 2018 7:33:43 AM
Is the pps a reflection of pricing in a failure? Quite possibly. Who's going to be right? I suspect we'll find out very soon. The catalysts for brilacidin alone bring this right back up, and then some imo.
Message in reply to:
These CROs are big and have very large capacity to handle multiple trials. P trial had only 199 patients.
In most cases the data is entered into the tool by sites directly as they have advance tools
The trial had 2 PE and 9 SE - only 1 PE and 4 SE depended on 16 week data. So by the time last patient visit on Dec 21st - most of the 12 week and 16 week data was already collected and available with CRO - and most likely entered into DB.
So the time taken for even giving primary outcome and say whether it met or not is suspiciously long.
Typically most of them issue PE results soon and if good/great, keep secondary and detailed results for scientific conf
In biotech - in my experience -
No news in 80% of the cases is bad news
Simply because tiny biotechs live on positive news cycle and die based on delayed or bad news
It clearly seems to me that P results are not going to be that great and Leo is trying to time it with some alternate news to reduce the blow.
But hey - this is already 40 cent share - it could soon become 10 cent
Go $IPIX
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
